NCT01385228 2018-06-06Pazopanib, Docetaxel, Prednisone ProstateDuke UniversityPhase 1 Completed36 enrolled
NCT00945477 2013-11-18Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen BlockadeIllinois CancerCare, P.C.Phase 2 Terminated11 enrolled 6 charts